Retatrutide

What it is

Retatrutide (development code LY3437943) is an investigational triple receptor agonist targeting the GLP-1, GIP, and glucagon receptors, under development for obesity and type 2 diabetes.S1S2

Marketed as

Because it is not approved, retatrutide has no approved marketing. It is discussed in manufacturer trial communications for weight loss and metabolic disease, and — ahead of any approval — is promoted on the gray market and by research-chemical sellers. Any such promotion describes an investigational compound, not an approved therapy.S2

Regulatory status (US)

Retatrutide is not FDA-approved and is not legally available for prescription or purchase; it is an investigational drug still in clinical trials.S2

Around the world

Retatrutide is not an approved medicine in any country; it exists within manufacturer-run clinical trials, not as a licensed product.S1S2

Evidence

Late-stage trial data reported by the manufacturer describe substantial weight reduction in Phase 3 obesity studies.S1 These are manufacturer-reported investigational results, not the basis of an approved label, and should be framed as preliminary pending peer-reviewed publication and regulatory review.S1S2

Anti-doping

Retatrutide's specific status should be checked against the current WADA List; as of 2026 the incretin-agonist class is under WADA monitoring rather than prohibition (see caveat).S3

Safety

There is no FDA-approved safety labeling for retatrutide; safety information comes only from ongoing trials.S1 Gray-market material sold under this name carries the usual unapproved-peptide concerns — unknown identity, purity, and dosing — and is outside any regulated oversight.S2

What's changing

The item to watch is retatrutide's Phase 3 completion and any FDA submission; until then it remains investigational.S1S2